Table 1.
Patient, disease, and treatment characteristics.
| Variables | Palliative Intent Treatment, n (%) |
Curative Intent Treatment, n (%) |
|---|---|---|
| Sex | ||
| Male | 25 (44) | 17 (33) |
| Female | 20 (56) | 35 (67) |
| Median age at treatment start ‡ | 66 (37–92) | 66 (28–84) |
| KPS prior to treatment | ||
| 100 | 14 (31) | 25 (48) |
| 90 | 7 (16) | 6 (12) |
| ≤80 | 14 (31) | 5 (10) |
| n.a. | 10 (22) | 16 (30) |
| Primary tumor histology | ||
| Breast cancer | 11 (25) | 22 (42) |
| Lung cancer | 5 (11) | 0 (0) |
| Bladder cancer | 2 (4) | 7 (13) |
| Anal cancer | 4 (9) | 2 (4) |
| Rectal cancer | 4 (9) | 6 (11) |
| Melanoma | 6 (13) | 0 (0) |
| Sarcoma | 1 (2) | 5 (10) |
| Pancreas cancer | 0 (0) | 5 (10) |
| Prostate cancer | 5 (11) | 2 (4) |
| Other | 7 (16) * | 3 (6) ** |
| Recurrent cancer | 25 (56) | 32 (62) |
| RT prescribed total dose (Gy) † | 38 (±10) | 50 (±6) |
| RT dose per fraction (Gy) † | 2.5 (±0.5) | 1.9 (±0.2) |
| Number of RT fractions † | 16 (±7) | 24 (±4) |
| Duration of RT + HT (days) † | 25 (±13) | 35 (±8) |
| HT techniques | ||
| Superficial HT | 22 (49) | 27 (52) |
| Deep regional HT | 23 (51) | 25 (48) |
| Time interval between RT and HT (minutes) ‡ | 15 (7–80) | 14 (6–83) |
| n.a. | 3 (7) | 7 (13) |
| Total HT sessions ‡ | 5 (3–11) | 5 (4–11) |
| Temperature metrics (°C) | ||
| Tavg † | 39.9 (±0.7) | 40.3 (±0.6) |
| Tmax † | 40.5 (±0.8) | 40.9 (±0.6) |
| n.a. | 11 (32) | 10 (19) |
| Thermal dose CEM43 † | 1.7 (±1.5) | 2.8 (±2.2) |
| n.a. | 11 (32) | 10 (19) |
| Chemotherapy | ||
| Superficial HT | 0 (0) | 0 (0) |
| Deep regional HT | 1 (4) | 14 (27) |
‡: median (range); †: mean (± standard deviation); n.a.: not available; *: cervical (n = 1), gastroesophageal cancer (n = 1), liver cancer (n = 2), parotid glad (n = 1), renal cell carcinoma (n = 1), thyroid (n = 1); **: bone cancer (n = 1), cervical cancer (n = 1), hypopharyngeal cancer (n = 1).